Vaccine Equity Strategy

Vaccine Equity Strategy in SCD
Given the wide-ranging reasons for vaccine hesitancy, there is a strong need for evidence-based, community-informed vaccine resources, especially for people affected by Sickle Cell Disease (SCD) who are susceptible to infections. Through its Vaccine Equity in SCD (VES) Study, the SCAGO intends to work with patients with SCD, their families, caregivers, and clinicians to co-design and implement a Vaccination Equity Strategy in SCD to support policymakers, health agencies, hospitals etc. with valuable insight to achieving vaccine equity (what works for the sickle cell community) and support the sickle cell disease community with fact-based vaccine information.

To participate in the study, complete the registration form or send an email to Questions/comments can be directed to the VES Team at